Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Clinical and Vaccine Immunology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
MICROBIAL IMMUNOLOGY

Impaired Gamma Interferon Response to Mycobacterium vaccae Antigens in Patients with Cavitary Pulmonary Tuberculosis

Elisabeth Rodríguez-Güell, Gemma Agustí, Mercè Corominas, Marina Luquin, Esther Julián
Elisabeth Rodríguez-Güell
1Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, 08193, Bellaterra, Catalonia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gemma Agustí
1Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, 08193, Bellaterra, Catalonia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mercè Corominas
2Servei d'Al·lèrgia, Hospital Universitari de Bellvitge, 08907, L'Hospitalet de Llobregat, Catalonia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marina Luquin
1Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, 08193, Bellaterra, Catalonia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esther Julián
1Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, 08193, Bellaterra, Catalonia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: esther.julian@uab.es
DOI: 10.1128/CVI.00131-08
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The ability of tuberculosis patients to recognize Mycobacterium vaccae-specific antigens before starting chemotherapy and according to disease severity was analyzed. We report that the M. vaccae cell wall skeleton fraction triggers more enhanced cytokine production than the whole bacterium. Moreover, a tendency was observed for a lower gamma interferon/interleukin-10 ratio in patients with cavitary disease induced by M. vaccae antigens.

The saprophytic Mycobacterium vaccae is being tested as an immunotherapeutic agent in tuberculosis (TB). It is supposed to boost a cross-protective immune response to epitopes shared with Mycobacterium tuberculosis. However, the efficiency of a single injected dose of M. vaccae varied between different clinical trials (14). The causes of this variability are not clear, but the immune status background of the patients (11, 14) or differences in the disease severity (6) could have been influential. Evidence from some of these trials suggests that M. vaccae immunotherapy induces an enhancement of protective gamma interferon (IFN-γ) levels, together with a reduction in circulating interleukin-10 (IL-10) levels (3). In fact, a reverse relationship between the M. tuberculosis antigen-induced IFN-γ/IL-10 ratio and disease severity in TB (5) and also a direct relationship between the IFN-γ/IL-10 ratio with TB cure (1, 12) have been demonstrated in a large-scale analysis. However, no data are available on the ability of the immune systems of TB patients to recognize M. vaccae-specific antigens before starting anti-TB chemotherapy and according to TB severity.

Herein, we analyze the IFN-γ- and IL-10-induced responses in peripheral blood mononuclear cells (PBMC) of TB patients, using both M. tuberculosis and, for the first time, M. vaccae and its cell wall skeleton (CWS) fraction. We have recently demonstrated that the CWS fraction elicits a prominent recall IFN-γ response in splenocyte cultures from mice with TB in comparison with the whole bacterium (10).

Blood samples were collected from adult pulmonary TB patients admitted to the Tuberculosis Unit-Infectious Diseases Service of the Bellvitge Hospital (Spain), before starting chemotherapy. In all cases the disease was confirmed by isolation of M. tuberculosis in cultures. All patients were tuberculin skin test positive and had not been previously Mycobacterium bovis BCG vaccinated. None of the patients had human immunodeficiency virus coinfection, M. tuberculosis reinfection, or other diseases that could affect the immune response. According to the presence of lung cavitation at the time of chest X-ray examination, the patients were classified as affected by noncavitary (n = 4 patients) or cavitary (n = 9 patients) pulmonary TB. Ten blood samples were also taken from healthy tuberculin skin test-negative employees at the hospital. The study was approved by the Ethics Committee of Clinical Investigation of Bellvitge Hospital, and written informed consent was obtained from all participants.

Cells of a stable rough variant of M. vaccae strain ATCC 15483T and M. tuberculosis H37Rv (ATCC 27294T) were heat killed and diluted as described previously (9). The CWS fraction was obtained as described previously (10). All antigens were frozen at −40°C until use. Isolated PBMC were cultured at 2 × 106 cells/ml in Iscove's modified Dulbecco's medium containing 10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin and were stimulated using phytohemagglutinin (Sigma, St. Louis, MO) at 1:300 as a positive control, M. tuberculosis (10 μg/ml), M. vaccae (10 μg/ml), CWS (5 μg/ml), or medium alone as a negative control. Culture supernatants were collected after 48 h of culture (for IL-10 quantification) or 120 h (for IFN-γ), and cytokine concentrations were measured by enzyme-linked immunosorbent assays using commercially available kits (Mabtech AB, Stockholm, Sweden).

Cytokine levels were compared using a two-tailed Mann-Whitney rank sum or Wilcoxon signed rank test, linear regression analysis, and Spearman's rank correlation, as indicated in the figure legends and table footnotes. A P value of <0.05 was considered significant.

Analyzing the response for each TB patient individually, we observed a strong positive correlation between M. tuberculosis- and M. vaccae-induced IFN-γ production (r = 0.937; P < 0.001) and IL-10 production (r = 0.923; P < 0.001) and also between M. tuberculosis- and CWS-induced IFN-γ production (r = 0.916; P < 0.001) and IL-10 production (r = 0.895; P < 0.001). When comparing M. vaccae- and CWS-induced IFN-γ or IL-10 production, there was again a significant positive correlation in each TB patient (Fig. 1). However, although each patient reacted in the same way to both M. vaccae and CWS, remarkably, the CWS not only retained the immune-stimulatory ability of the whole bacterium but also triggered enhanced cytokine production in TB patients (Table 1). In all cases the cytokine levels in cultures from healthy controls were lower than those obtained from TB patients (Table 1).

Our results also showed different patterns of responses to M. vaccae and CWS antigens among TB patients. Seven out of 12 patients showed impaired IFN-γ production compared to IL-10 production, i.e., samples F to L (Table 1), showing an IFN-γ/IL-10 index lower than 1. However, the remainder of the patients (samples A to E) had an index higher than 1. When we correlated these results with the radiographic manifestation of the disease, a tendency towards a lower IFN-γ/IL-10 ratio in patients with cavitary disease was observed, i.e., 85.7% of the patients (six out of seven) with a ratio lower than 1 had cavitation in their lungs (Table 1).

A clear increase in cytokine levels in noncavitary versus cavitary TB patients was observed (Fig. 2). Although the median ratio showed a log difference among groups, the differences were statistically significant only in the case of M. tuberculosis-induced IFN-γ detection (Fig. 2). Although the specific cytokine response against M. vaccae antigens in cavitary and noncavitary TB patients has not been studied before, diminished Th1 responses to M. tuberculosis antigens in PBMC from TB patients have been directly correlated with the severity of the disease (2, 8, 13, 15). Our findings further support these previous observations (Fig. 2). This is an interesting point because one of the initially reported benefits of M. vaccae immunotherapy was the improvement in chest radiographic healing or cavity closure (14). Johnson et al. (7) specifically analyzed the effect of one injected dose of M. vaccae on radiographic response in three large trials and did not observe any benefit. On the contrary, studies in which three or five doses of M. vaccae were administered showed its efficacy for healing and closing cavities in TB patients (4, 14). These previous studies together with our results lead us to believe that patients showing an impaired M. vaccae-induced IFN-γ response in vitro will not respond to one dose of M. vaccae administration in vivo. Therefore, the in vitro analysis of the M. vaccae-specific immune responses in each TB patient could be indicative of the outcome of the in vivo administration, which may be of interest in understanding the unsuccessful results and the requirement of many injected doses among patients whose Th1-type responses are decreased.

Although larger studies are needed to confirm these preliminary findings, our results showed that the CWS fraction appeared to be a possible immunotherapeutic agent candidate, confirming the previous results obtained in mouse experiments (10). Furthermore, the results suggest an association between the in vitro reactions to M. vaccae antigens with disease severity, suggesting a different capability to respond to in vivo immunotherapy.

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

Correlation of IFN-γ and IL-10 production in TB patients for each stimulus (M. vaccae and CWS antigens). A significant correlation was found between IFN-γ and IL-10 production after in vitro stimulation with the M. vaccae or CWS antigen. This was confirmed by Spearman's rank correlation coefficients (r = 0.93 and P < 0.001 for IFN-γ production; r = 0.972 and P < 0.001 for IL-10 production).

FIG. 2.
  • Open in new tab
  • Download powerpoint
FIG. 2.

IFN-γ and IL-10 production in pulmonary TB patients and healthy controls in response to CWS, M. vaccae, or M. tuberculosis antigens. The boxes extend from the 25th to the 75th percentiles, with a line at the median, and the whiskers show the highest and lowest values. Empty boxes represent IFN-γ production and scattered boxes show IL-10 production. A dot represents one out-of-order value. Median levels of M. tuberculosis-induced IFN-γ in noncavitary TB patients were significantly higher than those produced in cavitary TB patients (*, P < 0.05; measured using the two-tailed Mann-Whitney rank sum test).

View this table:
  • View inline
  • View popup
TABLE 1.

IFN-γ and IL-10 production in PBMC cultures from pulmonary TB patients and healthy subjects

ACKNOWLEDGMENTS

We are deeply indebted to Lucia González, Mar Lázaro, Luisa Luquin, Gabriel Rufí, and Miguel Santín of the Hospital Universitari de Bellvitge for their help in collecting the samples. G. Rufí passed away in December 2005.

This work was supported by grants from the Ministerio de Ciencia y Tecnología (SAF2002-00514), the Generalitat de Catalunya (SGR2005-00956), and the Fundació La Marató de TV3 (041230/1).

FOOTNOTES

    • Received 13 April 2008.
    • Returned for modification 11 June 2008.
    • Accepted 27 June 2008.
  • Copyright © 2008 American Society for Microbiology

REFERENCES

  1. 1.↵
    Al-Attiyah, R., A. S. Mustafa, A. T. Abal, N. M. Madi, and P. Andersen. 2003. Restoration of mycobacterial antigen-induced proliferation and interferon-gamma responses in peripheral blood mononuclear cells of tuberculosis patients upon effective chemotherapy. FEMS Immunol. Med. Microbiol.38:249-256.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Dlugovitzky, D., M. L. Bay, L. Rateni, G. Fiorenza, L. Vietti, M. A. Farroni, and O. A. Bottasso. 2000. Influence of disease severity on nitrite and cytokine production by peripheral blood mononuclear cells (PBMC) from patients with pulmonary tuberculosis (TB). Clin. Exp. Immunol.122:343-349.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Dlugovitzky, D., O. Bottasso, J. C. Dominino, E. Valentini, R. Hartopp, M. Singh, C. Stanford, and J. Stanford. 1999. Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172). Respir. Med.93:557-562.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Dlugovitzky, D., G. Fiorenza, M. Farroni, C. Bogue, C. Stanford, and J. Stanford. 2006. Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis. Respir. Med.100:1079-1087.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    Jamil, B., F. Shahid, Z. Hasan, N. Nasir, T. Razzaki, G. Dawood, and R. Hussain. 2007. Interferon gamma/IL-10 ratio defines the disease severity in pulmonary and extra pulmonary tuberculosis. Tuberculosis87:279-287.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Johnson, J. L., R. M. Kamya, A. Okwera, A. M. Loughlin, S. Nyole, D. L. Hom, R. S. Wallis, C. S. Hirsch, K. Wolski, J. Foulds, R. D. Mugerwa, and J. J. Ellner. 2000. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. J. Infect. Dis.181:1304-1312.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Johnson, J. L., A. J. Nunn, P. B. Fourie, L. P. Ormerod, R. D. Mugerwa, A. Mwinga, C. Chintu, B. Ngwira, P. Onyebujoh, and A. Zumla. 2004. Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis. Int. J. Tuberc. Lung Dis.8:1348-1354.
    OpenUrlPubMed
  8. 8.↵
    Mazzarella, G., A. Bianco, F. Perna, D. D'Auria, E. Grella, E. Moscariello, and A. Sanduzzi. 2003. T lymphocyte phenotypic profile in lung segments affected by cavitary and non-cavitary tuberculosis. Clin. Exp. Immunol.132:283-288.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    Rodríguez-Güell, E., G. Agustí, M. Corominas, P.-J. Cardona, I. Casals, T. Parella, M. A. Sempere, M. Luquin, and E. Julián. 2006. The production of a new extracellular putative long-chain saturated polyester by smooth variants of Mycobacterium vaccae interferes with Th1-cytokine production. Antonie van Leeuwenhoek90:93-108.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    Rodríguez-Güell, E., G. Agustí, M. Corominas, P. J. Cardona, M. Luquin, and E. Julián. 2008. Mice with pulmonary tuberculosis treated with Mycobacterium vaccae develop strikingly enhanced recall gamma interferon responses to M. vaccae cell wall skeleton. Clin. Vaccine Immunol.15:893-896.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Rook, G. A., K. Dheda, and A. Zumla. 2005. Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat. Rev. Immunol.5:661-667.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    Sahiratmadja, E., B. Alisjahbana, T. de Boer, I. Adnan, A. Maya, H. Danusantoso, R. H. Nelwan, S. Marzuki, J. W. van der Meer, R. van Crevel, E. van de Vosse, and T. H. Ottenhoff. 2007. Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment. Infect. Immun.75:820-829.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    Sodhi, A., J. Gong, C. Silva, D. Qian, and P. F. Barnes. 1997. Clinical correlates of interferon gamma production in patients with tuberculosis. Clin. Infect. Dis.25:617-620.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Stanford, J., C. Stanford, and J. Grange. 2004. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front. Biosci.9:1701-1719.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    Wu, H. P., C. C. Hua, and D. Y. Chuang. 2007. Decreased in vitro interferon-gamma production in patients with cavitary tuberculosis on chest radiography. Respir. Med.101:48-52.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Impaired Gamma Interferon Response to Mycobacterium vaccae Antigens in Patients with Cavitary Pulmonary Tuberculosis
Elisabeth Rodríguez-Güell, Gemma Agustí, Mercè Corominas, Marina Luquin, Esther Julián
Clinical and Vaccine Immunology Sep 2008, 15 (9) 1485-1488; DOI: 10.1128/CVI.00131-08

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Email

Thank you for sharing this Clinical and Vaccine Immunology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Impaired Gamma Interferon Response to Mycobacterium vaccae Antigens in Patients with Cavitary Pulmonary Tuberculosis
(Your Name) has forwarded a page to you from Clinical and Vaccine Immunology
(Your Name) thought you would be interested in this article in Clinical and Vaccine Immunology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Impaired Gamma Interferon Response to Mycobacterium vaccae Antigens in Patients with Cavitary Pulmonary Tuberculosis
Elisabeth Rodríguez-Güell, Gemma Agustí, Mercè Corominas, Marina Luquin, Esther Julián
Clinical and Vaccine Immunology Sep 2008, 15 (9) 1485-1488; DOI: 10.1128/CVI.00131-08
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Antigens, Bacterial
Interferon-gamma
Mycobacterium
Tuberculosis, Pulmonary

Related Articles

Cited By...

About

  • About CVI
  • For Librarians
  • For Advertisers
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • Submit a Manuscript to mSphere

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 1556-6811; Online ISSN: 1556-679X